Systematic review and implemention progress of DOTS strategy

Abstract

Abstract: Objective To describe and review the implementation progress of DOTS strategy. Methods Through discussion with the invited experts, we determined the key words of retrival literature, and searched 12 database, 4 health agencies websites and Google Scholar. A total of 2182 papers between 1990—2010 were searched out including papers describing or evaluating DOTS strategy, cost-effectiveness analysis, experience on prevention and control. Results Of the 26 studies included in the analysis, 11 studies were WHO annual reports, 10 studies aimed to describe and evaluate DOTS strategy, 5 studies aimed to evaluate the effectiveness of DOTS strategy; the implementation of the DOTS strategy raised the cure rates by 13.1%-92.1%,the treatment success rate increased to 92.4%-95.0%, the registration rate increased by 163.0%-217.8%; prevalence rate and the loss rate decreased by 30.0%-50.0% and 73.0%-52.6% respectively. In addition, implementation of the DOTS strategy improved the cost-effectiveness as well. Conclusion The strong government commitment is prerequisite for sustainable implementation of the strategy, effective implementation of the DOTS strategy put the TB under control, meanwhile has a good cost-effectiveness.

Key words: Tuberculosis/prevention &, control, Health plan implementation, Cost-benefit analysis, Evaluation studies

CHENG Shi-ming, LIU Er-yong, WANG Fang, MA Yan, ZHOU Lin, WANG Li-xia, WAN Li-ya. Systematic review and implemention progress of DOTS strategy[J]. Chinese Journal of Antituberculosis, 2012, 34(9): 585-591.

References

［1］WHO. Global tuberculosis control report 2010. Geneva: World Health Organization, 2010.

［2］WHO. Global tuberculosis control: a short update to the 2009 report. Geneva:World Health Organization, 2009.

［3］WHO. Global tuberculosis control: Surveillance, Planning, Financing: WHO report 2008.Geneva: World Health Organization, 2008.

［4］WHO. Global tuberculosis control: Surveillance, Planning, Financing: WHO report 2007.Geneva: World Health Organization, 2007.

［5］WHO. Global tuberculosis control: Surveillance, Planning, Financing: WHO report 2006.Geneva: World Health Organization, 2006.

［6］WHO. Global tuberculosis control: Surveillance, Planning, Financing: WHO report 2005.Geneva: World Health Organization, 2005.

［7］WHO. Global tuberculosis control: Surveillance, Planning, Financing: WHO report 2004.Geneva: World Health Organization, 2004.

［8］WHO. Global tuberculosis control: Surveillance, Planning, Financing: WHO report 2003.Geneva: World Health Organization, 2003.

［9］WHO. Global tuberculosis control: Surveillance, Planning, Financing: WHO report 2002.Geneva: World Health Organization, 2002.

［10］WHO. Global tuberculosis control: WHO report 2001.Geneva: World Health Organization, 2001.

［11］WHO. Global tuberculosis control: WHO report 1997. Geneva: World Health Organization, 1997.

［12］Ushio M.Amendment of tuberculosis prevention law and prospect of tuberculosis control program. Kekkaku,2005,80(7):541-546.

［13］Shimao T. Tuberculosis prevalence survey in Japan. Kekkaku,2009, 84(11):713-720.

［14］Subramani R, Santha T, Frieden TR, et al. Active community surveillance of the impact of different tuberculosis control measures, Tiruvallur, South India, 1968—2001. Int J Epidemiol,2007,36(2):387-393.

［15］Xianyi C, Fengzeng Z, Hongjin D, et al. The DOTS strategy in China: results and lessons after 10 years. Bull World Health Organ, 2002,80(6):430-436.

［16］Yassin MA, Datiko DG, Shargie EB. Ten-year experiences of the tuberculosis control programme in the southern region of Ethiopia. Int J Tuberc Lung Dis,2006,10(10):1166-1171.

［17］China Tuberculosis Control Collaboration. The effect of tuberculosis control in China. Lancet,2004, 364(9432):417-422.

［18］Marica C, Didilescu C, Galie N, et al. Reversing the tuberculosis upwards trend: a success story in Romania. Eur Respir J,2009,33(1):168-170.

［19］Sharma S, Sarin R, Khalid UK, et al. The DOTS strategy for treatment of paediatric pulmonary tuberculosis in South Delhi,India.Int J Tuberc Lung Dis, 2008,12(1):74-80.

［20］Romero-Sandoval N, Flores-Carrera O, Molina MA, et al. DOTS strategy and community participation: an experience in the Ecuadorian Andes. Int J Tuberc Lung Dis,2009,13(12):1569-1571.

［21］Shargie EB,Lindtjorn B.DOTS improves treatment outcomes and service coverage for tuberculosis in South Ethiopia: a retrospective trend analysis. BMC Public Health, 2005,5:62.

［22］Zalesky R, Abdullajev F, Khechinashvili G, et al. Tuberculosis control in the Caucasus: successes and constraints in DOTS implementation.Int J Tuberc Lung Dis,1999,3(5):394-401.

［23］Subramani R, Radhakrishna S, Frieden TR, et al. Rapid decline in prevalence of pulmonary tuberculosis after DOTS implementation in a rural area of South India.Int J Tuberc Lung Dis,2008,12(8):916-920.

［24］Baltussen R, Floyd K, Dye C. Cost effectiveness analysis of strategies for tuberculosis control in developing countries. BMJ,2005,331(7529):1364.

［25］Pantoja A, Lonnroth K, Lal SS, et al. Economic evaluation of public-private mix for tuberculosis care and control, India. Part II. Cost and cost-effectiveness.Int J Tuberc Lung Dis,2009,13(6):705-712.

［26］Xu Q, Jin SG, Zhang LX. Cost effectiveness of DOTS and non-DOTS strategies for smear-positive pulmonary tuberculosis in Beijing. Biomed Environ Sci,2000,13(4):307-313.

［27］Murray CJ, DeJonghe E, Chum HJ, et al. Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries. Lancet,1991,338(8778):1305-1308.

［28］de Jonghe E, Murray CJ, Chum HJ,et al.Cost-effectiveness of chemotherapy for sputum smear-positive pulmonary tuberculosis in Malawi, Mozambique and Tanzania. Int J Health Plann Manage,1994, 9(2):151-181.

［29］Floyd K, Arora VK, Murthy KJ, et al. Cost and cost-effectiveness of PPM-DOTS for tuberculosis control: evidence from India.Bull World Health Organ, 2006,84(6):437-445.

［30］Raviglione MC,Sudre P,Rieder HL,et al.Secular trends of tuberculosis in western Europe. Bull World Health Organ,1993,71(3/4):297-306.

［31］Rieder HL, Cauthen GM, Comstock GW, et al. Epidemiology of tuberculosis in the United States. Epidemiol Rev,1989,11:79-98.

［32］McKenna MT, McCray E, Onorato I. The epidemiology of tuberculosis among foreign-born persons in the United States, 1986 to 1993. N Engl J Med, 1995,332(16):1071-1076.

［33］Suárez PG, Watt CJ, Alarcón E,et al. The dynamics of tuberculosis in response to 10 years of intensive control effort in Peru. J Infect Dis, 2001,184(4):473-478.

［34］Frieden TR. Can tuberculosis be controlled? Int J Epidemiol, 2002,31(5):894-899.

［35］Frieden TR, Fujiwara PI, Washko RM, et al. Tuberculosis in New York City—turning the tide. N Engl J Med,1995,333(4):229-233.

[1]	JIN Hong-jian. The construction of tuberculosis prevention and control service system at county level in China needs to be strengthened urgently —— Comments and suggestions of an old tuberculosis control and prevention worker [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 896-902.
[2]	ZHU Li-mei, CHEN Can-can, CHEN Wei, HU Xiao-guang, ZHANG Ya-nan, MA Jun-yang. To formulate prevention and control strategy for latent tuberculosis infection population in China [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 794-798.
[3]	ZHANG Kai, SHEN Xiao-bing, TAO Li-feng, WEI Fen, CHEN Bao-wen, QIU Jing-jing, CHEN Wei, LU Jin-biao, ZHU Yin-meng, CHENG Xing, ZHONG Zai-xin, ZHAO Ai-Hua, PU Jiang. Establishment of quality standards for recombinant Mycobacterium tuberculosis fusion protein [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 814-820.
[4]	CHEN Feng-fang, MA Jun, HUANG Jin, YIN Hong-yun, SHA Wei, YANG Guang-hong, FENG Yong-hong. Preliminary study on establishing the diagnostic model for smear negative tuberculosis and stage Ⅰ/Ⅱ sarcoidosis with hilar/mediastinal lymphadenopathy and positive T-SPOT.TB results [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 832-837.
[5]	DUAN Li-ming, DING Chao, LIU Yu-gang, WEI Lin, GU Zhen-ning. Application value of video-assisted thoracoscopic surgery in the treatment of chronic tuberculous empyema [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 850-853.
[6]	YANG Lu-qi, SHEN Ming-yi, SHA Wei, CHEN Ying-ying, WANG Ying. Research progress in immunoprotective mechanism of bacille Calmette-Guérin and vaccine development strategies [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 863-868.
[7]	SHEN Xin, SHA Wei, LIU Jian-jun. Impact of coronavirus disease 2019 (COVID-19) on tuberculosis control and countermeasures in China [J]. Chinese Journal of Antituberculosis, 2020, 42(6): 544-548.
[8]	ZHANG Pei-ze, FU Liang, TAN Jie, WANG Yu-xiang, CHEN Tao, DENG Guo-fang. CT imaging characteristics of cured multidrug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(6): 558-562.
[9]	LI Jin,GUO Xiao-qin,LI Yong,ZOU Jin-yan,LU Li-ping. Analysis on the effect of active screening of tuberculosis among local people aged 65 or older in Songjiang District of Shanghai in 2018 [J]. Chinese Journal of Antituberculosis, 2020, 42(4): 353-359.
[10]	GAO Qian,MEI Jian. Reflections on the prevention and control of tuberculosis among Chinese students [J]. Chinese Journal of Antituberculosis, 2020, 42(3): 195-199.
[11]	CHEN Zhen-hua,LIU Bin-bin,CHEN Zhong-nan,TAN Yun-hong. Establishment and preliminary evaluation of a diagnostic model for the new patients with pathogen-negative pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(3): 266-271.
[12]	LIU Bin-bin,GONG Dao-fang,CHEN Zhen-hua,GUO Jing-wei,YU Yan-yan,LIU Feng-ping,OU-Yang hui,TAN Yun-hong. Comparative study on detection rate and detection cost of Mycobacterium tuberculosis complex by three laboratory diagnostic techniques [J]. Chinese Journal of Antituberculosis, 2020, 42(2): 143-148.
[13]	MA Gai-xia,TIAN Li-ming,WANG Yu,QIU Lei,XUE Ling-na,LU Zhen-hui,ZHANG Hui-yong,GUO Xiao-yan. Systematic evaluation and meta-analysis of integrated traditional Chinese and western medicine in the treatment of MDR-PTB [J]. Chinese Journal of Antituberculosis, 2020, 42(2): 95-100.
[14]	SUN Ming-lei, GUAN Li, ZHAO Juan, WANG Chen, ZOU Dan-dan, LIANG Li-bo. Legislative considerations on traffic travel of MDR-TB/XDR-TB patients from the perspective of infectious disease prevention and control [J]. Chinese Journal of Antituberculosis, 2020, 42(12): 1268-1271.
[15]	GU Ji-xiu, LI Qing, MA ling, LI Yin-hua, WANG Dong-dong, SI Hong-yan. Application of next-generation sequencing technology in the diagnosis of drug-resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(11): 1203-1208.